WASHINGTON, June 14 -- BioMarin Pharmaceutical Inc., San Rafael, California, has asked the U.S. Department of Commerce Bureau of Industry and Security to exclude orphan drugs and their components from any tariffs or import restrictions stemming from an ongoing Section 232 investigation into pharmaceutical imports. The biopharmaceutical company argues such an exclusion is justified due to the nature of orphan drugs and their market. G. Eric Davis, executive vice president and chief legal officer more ST

WASHINGTON, June 14 -- The Center for Individual Freedom has submitted comments to the U.S. Department of Commerce Bureau of Industry and Security, advocating for a judicious application of Section 232 of the Trade Expansion Act of 1962 to protect the nation's pharmaceutical supply chain. The non-profit organization urges a calibrated strategy that mitigates risks from adversarial nations while preserving relationships with trusted allies. The Center highlighted that America leads in pharmaceut more ST

WASHINGTON, June 14 -- Julia Baca, a lifelong horse owner, exhibitor, volunteer and community leader from Santa Fe, New Mexico, has submitted comments to the U.S. Department of Agriculture Animal and Plant Health Inspection Service regarding its proposed amendments to the Horse Protection Act. Baca argues that broad implementation of the rule could adversely affect horse organizations that already prioritize animal welfare. "Part of why I compete with and value these groups is because of the st more ST

WASHINGTON, June 14 -- The Government of Japan has submitted comments to the U.S. Department of Commerce Bureau of Industry and Security, urging against tariffs on pharmaceuticals and their ingredients. These comments, part of a Commerce investigation into pharmaceutical import effects on national security, highlight these products as critical to national security. The Japanese government contends it would be challenging for the U.S. to establish complete domestic manufacturing for all pharmace more ST

WASHINGTON, June 14 -- The Japan Pharmaceutical Manufacturers Association has submitted comments to the U.S. Department of Commerce Bureau of Industry and Security, opposing tariffs on pharmaceuticals and ingredients under a national security investigation. The association stressed its commitment to ensuring a stable supply of medicines vital to health security in both Japan and the U.S. The Japanese industry group highlighted a long history of zero tariffs between the nations, suggesting this  more ST

WASHINGTON, June 15 -- On Demand Pharmaceuticals, Rockville, Maryland, has submitted an analysis to the U.S. Department of Commerce Bureau of Industry and Security, outlining vulnerabilities within the nation's drug supply chains. The company states that the availability of essential medicines rests on assumptions that no longer hold, masking deeper issues across economic, structural and geopolitical lines. The company's assessment highlights that the U.S. heavily relies on global supply chains more ST

WASHINGTON, June 14 -- Alora Pharmaceuticals LLC, Alpharetta, Georgia, has submitted comments to the U.S. Department of Commerce Bureau of Industry and Security, regarding its Section 232 national security investigation on pharmaceutical imports. The company highlighted severe challenges posed by foreign competition to domestic production. Harold Arthur Deas Jr., CEO of Alora, explained the difficulty U.S. manufacturers face: "The market for Venlafaxine ER tablets is extremely competitive, with more ST